Lung cancer Posts on Medivizor
Navigation Menu

Lung cancer Posts on Medivizor

Can nivolumab plus ipilimumab combined with chemotherapy be used as a first-line treatment for patients with non-small cell lung cancer?

Can nivolumab plus ipilimumab combined with chemotherapy be used as a first-line treatment for patients with non-small cell lung cancer?

Posted by on May 6, 2021 in Lung cancer | 0 comments

In a nutshell This trial looked at nivolumab (Opdivo) plus ipilimumab (Yervoy) combined with 2 cycles of chemotherapy as treatment for patients with non-small cell lung cancer (NSCLC). The authors found that this combination provided an improved overall survival versus chemotherapy-only regimens. Some background NSCLC is responsible for 85% of...

Read More

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by on Apr 30, 2021 in Lung cancer | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including lung cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Read More

Should durvalumab be considered a first-line treatment for extensive small cell lung cancer?

Should durvalumab be considered a first-line treatment for extensive small cell lung cancer?

Posted by on Apr 30, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at the effectiveness of durvalumab (Imfinzi) with or without tremelimumab plus platinum-etoposide (Etopophos) (PE) versus PE-alone for the treatment of extensive-stage small-cell lung cancer (ESCLC). The authors found that durvalumab plus PE showed sustain survival improvement in these patients. Some background...

Read More

Evaluating the outcomes of prophylactic cranial irradiation for the treatment of non-small cell lung cancer with a high-risk of developing brain metastases

Evaluating the outcomes of prophylactic cranial irradiation for the treatment of non-small cell lung cancer with a high-risk of developing brain metastases

Posted by on Apr 30, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and outcomes of using prophylactic cranial irradiation (PCI) in patients with non-small cell lung cancer (NSCLC) with a high risk for developing brain metastases (BM). The data showed that PCI significantly decreased the risk of developing BM and increased the overall survival in these...

Read More

Is C-reactive protein associated with survival in patients with non-small cell lung cancer treated with atezolizumab?

Is C-reactive protein associated with survival in patients with non-small cell lung cancer treated with atezolizumab?

Posted by on Apr 25, 2021 in Lung cancer | 0 comments

In a nutshell This study was carried out to see whether a reduction in inflammatory marker C-reactive protein (CRP) following treatment with atezolizumab (Tecentriq) is associated with an improved survival in patients with non-small cell lung cancer (NSCLC). The authors found that a lower CRP following treatment was associated with improved...

Read More

Can stereotactic body radiotherapy can be used as an alternative to minimal invasive surgery for early-stage non-small cell lung cancer?

Can stereotactic body radiotherapy can be used as an alternative to minimal invasive surgery for early-stage non-small cell lung cancer?

Posted by on Apr 10, 2021 in Lung cancer | 0 comments

In a nutshell This article compared the use of video-assisted thoracoscopic lobectomy (VATL) versus stereotactic body radiotherapy (SBRT) for the treatment of early-stage non-small cell lung cancer (NSCLC). The authors found that SBRT could provide an alternative treatment option for these patients.  Some background Early-stage NSCLC is...

Read More

Do single or combined immune checkpoint inhibitors improve outcomes in patients with advanced non-small cell lung cancer?

Do single or combined immune checkpoint inhibitors improve outcomes in patients with advanced non-small cell lung cancer?

Posted by on Apr 8, 2021 in Lung cancer | 0 comments

In a nutshell This article looked at the effectiveness and safety of first-line immune checkpoint inhibitors (ICIs) alone or as a combination compared to platinum-based chemotherapy (PBC) for advanced non-small cell lung cancer (NSCLC). The authors found that ICI therapy may improve the survival of these patients while having reduced side...

Read More

Should ipilimumab and nivolumab treatment be considered before surgery in operable non-small cell lung cancer?

Should ipilimumab and nivolumab treatment be considered before surgery in operable non-small cell lung cancer?

Posted by on Apr 4, 2021 in Lung cancer | 0 comments

In a nutshell This trial was carried out to look at the effectiveness of nivolumab (Opdivo) and nivolumab plus ipilimumab (Yervoy) as neoadjuvant therapy (NAT; treatment before surgery) in treating operable non-small cell lung cancer (NSCLC). The authors found that ipilimumab and nivolumab treatment before surgery provides better...

Read More

Should immunotherapy and radiotherapy be considered as an effective treatment for non-small cell lung cancer?

Should immunotherapy and radiotherapy be considered as an effective treatment for non-small cell lung cancer?

Posted by on Apr 3, 2021 in Lung cancer | 0 comments

In a nutshell This article analyzed the safety and effectiveness of an immunotherapy (IT) and radiotherapy (RT) combination to treat patients with non-small cell lung cancer (NSCLC). The authors found that combination therapy using an immunotherapy drug such as PD-1/PD-L1 inhibitors and RT may improve the outcomes of these patients. Some background...

Read More

Is olmutinib effective in treating T790M-positive unresponsive non-small cell lung cancer?

Is olmutinib effective in treating T790M-positive unresponsive non-small cell lung cancer?

Posted by on Apr 3, 2021 in Lung cancer | 0 comments

In a nutshell This article looked at the use of olmutinib (Olita) in the treatment of T790M-positive non-small cell lung cancer (NSCLC) that was previously unresponsive to a tyrosine kinase inhibitor (TKI). The authors concluded that olmutinib had clinical activity and manageable side effects in these patients. Some background NSCLC accounts for...

Read More

How does durvalumab impact the treatment of unresectable stage III non-small cell lung cancer based on previous treatment?

How does durvalumab impact the treatment of unresectable stage III non-small cell lung cancer based on previous treatment?

Posted by on Mar 14, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at the outcomes of durvalumab (Imfinzi) in patients with unresectable (cannot be surgically removed) stage 3 non-small cell lung cancer (NSCLC) who received different combinations of chemoradiotherapy (CRT) previously. The authors found that the use of durvalumab improved survival in all patients previously treated...

Read More